Trial Search Results
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.
Stanford is currently not accepting patients for this trial.
Collaborator: Merz Pharmaceuticals GmbH
- Drug: Memantine - Extended Release (ER)
- Drug: Placebo
- Males or females ages 6 to 12 years
- Diagnosis of autistic disorder, according to DSM-IV-TR using Autism Diagnostic
Interview-Revised and Autism Diagnostic Observation Schedule (modules 2 & 3).
- A knowledgeable caregiver capable of providing reliable information about the
patient's condition, able to attend all clinic visits with the patient
- Patients over age 12, only if they completed Study MEM-PK-21
- Medical history of active epilepsy/seizure disorder except simple febrile seizures
- Participation in any other clinical investigation using an experimental drug within 30
days of the start of this study
Ages Eligible for Study
6 Years - 18 Years
Genders Eligible for Study